



## **BrainCool AB (publ) – new order for BrainCool™ System in Germany**

BrainCool has received yet another order in Germany, this time from Krankenhaus Martha-Maria in Halle, for the product BrainCool™ System. The order of one system is for cooling treatment of cardiac arrest patients. Delivery is expected at the beginning of April.

CEO Martin Waleij comments:

This order is a confirmation that the market for medical technology in intensive care is prioritized even during the turbulence with Covid-19. Furthermore, the product is implemented in the treatment chain as a result of patients being initially treated with RhinoChill™, and then being transferred to the BrainCool™ System for treatment at the ICU.

*This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out herein, on March 31, 2020.*

### **For more information**

Martin Waleij – CEO

+46 - 733 -93 70 76

E-mail: [martin.waleij@braincool.se](mailto:martin.waleij@braincool.se)

### **About BrainCool AB (publ)**

*BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Pain Management. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Spotlight Stock Market.*